Docoh
Loading...

ANIX Anixa Biosciences

Anixa Biosciences Inc. is a biotechnology company developing a number of programs addressing cancer and infectious disease. Anixa's therapeutics portfolio includes a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology, and a Covid-19 therapeutics program focused on inhibiting certain viral protein function. The company's vaccine portfolio includes a vaccine to prevent breast cancer, and specifically triple negative breast cancer (TNBC), the most deadly form of the disease, and a vaccine to prevent ovarian cancer. These vaccine technologies focus on immunizing against specific proteins that have been found to be expressed in certain forms of cancer. Anixa continually examines emerging technologies in complementary fields for further development and commercialization.

Company profile

Ticker
ANIX
Exchange
Website
CEO
Amit Kumar
Employees
Incorporated
Location
Fiscal year end
Former names
COPYTELE INC, ITUS Corp
SEC CIK
IRS number
112622630

ANIX stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

10 Jun 21
28 Jul 21
31 Oct 21
Quarter (USD)
Apr 21 Jan 21 Oct 20 Jul 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Oct 20 Oct 19 Oct 18 Oct 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 27.7M 27.7M 27.7M 27.7M 27.7M 27.7M
Cash burn (monthly) (positive/no burn) (positive/no burn) 812.43K 779.05K 413.83K 426.41K
Cash used (since last report) n/a n/a 2.39M 2.29M 1.22M 1.26M
Cash remaining n/a n/a 25.31M 25.41M 26.49M 26.45M
Runway (months of cash) n/a n/a 31.2 32.6 64.0 62.0

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
23 Jul 21 Baskies Arnold M Common Stock Buy Aquire P No No 4.33 19,000 82.27K 100,000
23 Jul 21 Kumar Amit Common Stock Buy Aquire P No No 4.28 5,000 21.4K 292,000
16 Jul 21 Kumar Amit Common Stock Buy Aquire P No No 3.94 10,000 39.4K 287,000
15 Jul 21 Baskies Arnold M Common Stock Buy Aquire P No No 3.9 20,000 78K 81,000
15 Jul 21 Emily Gottschalk Common Stock Buy Aquire P No No 3.96 20,065 79.46K 45,665

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

13F holders
Current Prev Q Change
Total holders 0 0
Opened positions 0 0
Closed positions 0 0
Increased positions 0 0
Reduced positions 0 0
13F shares
Current Prev Q Change
Total value 0 0
Total shares 0 0
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners
Shares Value Change
Largest transactions
Shares Bought/sold Change
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: aforementioned, agent, assigned, behavior, combinatorial, deal, deducting, director, fourth, improving, innovative, interception, longer, loosening, mammary, medicinal, MolGenie, monitoring, NCI, noticeable, optimize, outlook, preclinical, proceed, request, showed, stage, synthetic, underwriter, underwriting, virtually, withheld, woman
Removed: calendar, capitalized, classification, commencement, deposit, expedient, filing, forgo, hindsight, initial, issue, package, policy, practical, reassessing, vested